SP1049C is a novel anthracycline chemotherapeutic agent containing doxorubicin and two nonionic pluronic block copolymers. It is designed to overcome drug resistance in a number of cancers. It has successfully... It has successfully completed Phase 1 trials.
- Mechanism
- Curator reviewed
SP1049C is a novel anticancer agent containing doxorubicin and two nonionic pluronic block copolymers. Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
- Primary indication
- Intended for the treatment of carcinoma of the oesophagus.Curator reviewed
- Also known as
- Doxorubicin HCl with pluronic L-61 and pluronic F-127 · doxorubicin with pluronics F-127 and L-61
- Code names
- SP1049C
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with SP1049C, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account